These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 34152821

  • 1. Effective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection.
    Chiu JE, Renard I, Pal AC, Singh P, Vydyam P, Thekkiniath J, Kumar M, Gihaz S, Pou S, Winter RW, Dodean R, Frueh L, Nilsen AC, Riscoe MK, Doggett JS, Mamoun CB.
    Antimicrob Agents Chemother; 2021 Aug 17; 65(9):e0066221. PubMed ID: 34152821
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.
    Vydyam P, Chand M, Pou S, Winter RW, Liebman KM, Nilsen A, Doggett JS, Riscoe MK, Ben Mamoun C.
    ACS Infect Dis; 2024 Apr 12; 10(4):1405-1413. PubMed ID: 38563132
    [Abstract] [Full Text] [Related]

  • 3. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone.
    Lawres LA, Garg A, Kumar V, Bruzual I, Forquer IP, Renard I, Virji AZ, Boulard P, Rodriguez EX, Allen AJ, Pou S, Wegmann KW, Winter RW, Nilsen A, Mao J, Preston DA, Belperron AA, Bockenstedt LK, Hinrichs DJ, Riscoe MK, Doggett JS, Ben Mamoun C.
    J Exp Med; 2016 Jun 27; 213(7):1307-18. PubMed ID: 27270894
    [Abstract] [Full Text] [Related]

  • 4. Babesia duncani as a Model Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic Parasites In Vitro and In Vivo.
    Pal AC, Renard I, Singh P, Vydyam P, Chiu JE, Pou S, Winter RW, Dodean R, Frueh L, Nilsen AC, Riscoe MK, Doggett JS, Ben Mamoun C.
    J Infect Dis; 2022 Sep 28; 226(7):1267-1275. PubMed ID: 35512141
    [Abstract] [Full Text] [Related]

  • 5. Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
    Vydyam P, Pal AC, Renard I, Chand M, Kumari V, Gennaro JC, Mamoun CB.
    J Infect Dis; 2024 Jan 12; 229(1):161-172. PubMed ID: 38169301
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Establishment of a continuous in vitro culture of Babesia duncani in human erythrocytes reveals unusually high tolerance to recommended therapies.
    Abraham A, Brasov I, Thekkiniath J, Kilian N, Lawres L, Gao R, DeBus K, He L, Yu X, Zhu G, Graham MM, Liu X, Molestina R, Ben Mamoun C.
    J Biol Chem; 2018 Dec 28; 293(52):19974-19981. PubMed ID: 30463941
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cytochrome b Drug Resistance Mutation Decreases Babesia Fitness in the Tick Stages But Not the Mammalian Erythrocytic Cycle.
    Chiu JE, Renard I, George S, Pal AC, Alday PH, Narasimhan S, Riscoe MK, Doggett JS, Ben Mamoun C.
    J Infect Dis; 2022 Jan 05; 225(1):135-145. PubMed ID: 34139755
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Human Babesiosis: Then and Now.
    Renard I, Ben Mamoun C.
    Pathogens; 2021 Sep 01; 10(9):. PubMed ID: 34578153
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phosphatidylinositol 4-kinase is a viable target for the radical cure of Babesia microti infection in immunocompromised hosts.
    Ji S, Galon EM, Amer MM, Zafar I, Yanagawa M, Asada M, Zhou J, Liu M, Xuan X.
    Front Cell Infect Microbiol; 2022 Sep 01; 12():1048962. PubMed ID: 36452305
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Babesia duncani multi-omics identifies virulence factors and drug targets.
    Singh P, Lonardi S, Liang Q, Vydyam P, Khabirova E, Fang T, Gihaz S, Thekkiniath J, Munshi M, Abel S, Ciampossin L, Batugedara G, Gupta M, Lu XM, Lenz T, Chakravarty S, Cornillot E, Hu Y, Ma W, Gonzalez LM, Sánchez S, Estrada K, Sánchez-Flores A, Montero E, Harb OS, Le Roch KG, Mamoun CB.
    Nat Microbiol; 2023 May 01; 8(5):845-859. PubMed ID: 37055610
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens.
    Pudney M, Gray JS.
    J Parasitol; 1997 Apr 01; 83(2):307-10. PubMed ID: 9105316
    [Abstract] [Full Text] [Related]

  • 17. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.
    Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I.
    J Infect Dis; 2020 Aug 17; 222(6):1027-1036. PubMed ID: 32310272
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atovaquone in the treatment of Babesia microti infections in hamsters.
    Wittner M, Lederman J, Tanowitz HB, Rosenbaum GS, Weiss LM.
    Am J Trop Med Hyg; 1996 Aug 17; 55(2):219-22. PubMed ID: 8780464
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.